Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06805201 · ClinicalTrials.gov registry record · NA
The Effects of Gyngerlean Supplementation on Energy Expenditure
A NA study of Metabolism and No Disease or Condition is Being Studied, sponsored by Nova Southeastern University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06805201: Completed NA study of Metabolism and No Disease or Condition is Being Studied, sponsored by Nova Southeastern University.
NCT06805201 is a NA study of Metabolism and No Disease or Condition is Being Studied that has completed, run by Nova Southeastern University. The registered enrollment target is 10 participants, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06805201, a NA study of Metabolism and No Disease or Condition is Being Studied, has completed, sponsored by Nova Southeastern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized controlled study is to asses the effects of a ginger containing supplement on energy expenditure and substrate utilization in healthy men. The main questions it aims to answer are" * The effects of Kaempferia parviflora extract on energy expenditure * The effects of Kaempferia parviflora extract on substrate utilization
Primary Outcome
The amount of energy/calories the body needs to function while at rest.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Gyngerlean
Study Locations (1)
Florida
- Nova Southeastern University - Davie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2024-08-08 |
| Phase | NA |
What the finished NCT06805201 record still lists
NCT06805201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Metabolism appearing as the primary indexed condition, and to 1 intervention - of which Gyngerlean is the first listed.
NCT06805201 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06805201 about?
NCT06805201 is a clinical study titled "The Effects of Gyngerlean Supplementation on Energy Expenditure". The goal of this randomized controlled study is to asses the effects of a ginger containing supplement on energy expenditure and substrate utilization in healthy men. The main questions it aims to answer are" * The effects of Kaempferia parviflora extract on energy expenditure * The effects of Kaem...
What is the current status of trial NCT06805201?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2024-07-23. Estimated completion is 2024-08-08.
What conditions does trial NCT06805201 study?
This clinical trial studies the following conditions: Metabolism, No Disease or Condition is Being Studied.
What interventions are being tested in trial NCT06805201?
The interventions under investigation include: Gyngerlean (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06805201?
This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06805201 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06805201's enrollment target sits among peer trials
10 16th of 19 higher than 4 of 19 other Metabolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
RECRUITING · NA
-
Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
RECRUITING · NA
-
Personalized Responses to Dietary Composition Trial 3
RECRUITING · NA
-
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
ACTIVE NOT RECRUITING · NA
-
Duration of Physical Inactivity and Postprandial Lipid Metabolism
COMPLETED · NA
-
Effects of a Caffeine- and Protein-Containing Coffee Beverage on Metabolism and Muscular Performance
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI